Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer

Finn Ole Larsen; Per Pfeiffer; Dorte Nielsen; Kristin Skougaard; Camilla Qvortrup; Kirsten Vistisen; Anna-Lene Gunge Fromm; Trine Lembrecht Jørgensen; Jon Kroll Bjerregaard; Estrid Hoegdall; Benny V Jensen

doi:10.3109/0284186X.2010.546369

Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer

Finn Ole Larsen, Per Pfeiffer, Dorte Nielsen, Kristin Skougaard, Camilla Qvortrup, Kirsten Vistisen, Anna-Lene Gunge Fromm, Trine Lembrecht Jørgensen, Jon Kroll Bjerregaard, Estrid Hoegdall, Benny V Jensen

13 Citations (Scopus)

Abstract

The efficacy and safety of concurrent administration of irinotecan with the two monoclonal antibodies cetuximab and bevacizumab as fourth line therapy in heavily pretreated patients with metastatic colorectal cancer were evaluated.

Original language	English
Journal	Acta Oncologica
Volume	50
Issue number	4
Pages (from-to)	574-7
Number of pages	4
ISSN	0284-186X
DOIs	https://doi.org/10.3109/0284186X.2010.546369
Publication status	Published - 2011

Keywords

Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Camptothecin
Colorectal Neoplasms
Female
Humans
Liver Neoplasms
Male
Middle Aged
Mutation
Proto-Oncogene Proteins
Retrospective Studies
Survival Rate
Treatment Outcome
ras Proteins

Access to Document

10.3109/0284186X.2010.546369

Cite this

Larsen, F. O., Pfeiffer, P., Nielsen, D., Skougaard, K., Qvortrup, C., Vistisen, K., Fromm, A.-L. G., Jørgensen, T. L., Kroll Bjerregaard, J., Hoegdall, E., & Jensen, B. V. (2011). Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer. Acta Oncologica, 50(4), 574-7. https://doi.org/10.3109/0284186X.2010.546369

Larsen, FO, Pfeiffer, P, Nielsen, D, Skougaard, K, Qvortrup, C, Vistisen, K, Fromm, A-LG, Jørgensen, TL, Kroll Bjerregaard, J, Hoegdall, E & Jensen, BV 2011, 'Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer', Acta Oncologica, vol. 50, no. 4, pp. 574-7. https://doi.org/10.3109/0284186X.2010.546369

@article{a1169e5415f14a51b942918845013dd5,

title = "Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer",

abstract = "The efficacy and safety of concurrent administration of irinotecan with the two monoclonal antibodies cetuximab and bevacizumab as fourth line therapy in heavily pretreated patients with metastatic colorectal cancer were evaluated.",

keywords = "Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Colorectal Neoplasms, Female, Humans, Liver Neoplasms, Male, Middle Aged, Mutation, Proto-Oncogene Proteins, Retrospective Studies, Survival Rate, Treatment Outcome, ras Proteins",

author = "Larsen, \{Finn Ole\} and Per Pfeiffer and Dorte Nielsen and Kristin Skougaard and Camilla Qvortrup and Kirsten Vistisen and Fromm, \{Anna-Lene Gunge\} and J{\o}rgensen, \{Trine Lembrecht\} and \{Kroll Bjerregaard\}, Jon and Estrid Hoegdall and Jensen, \{Benny V\}",

year = "2011",

doi = "10.3109/0284186X.2010.546369",

language = "English",

volume = "50",

pages = "574--7",

journal = "Acta Oncologica",

issn = "0284-186X",

publisher = "Medical Journals Sweden AB",

number = "4",

}

TY - JOUR

T1 - Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer

AU - Larsen, Finn Ole

AU - Pfeiffer, Per

AU - Nielsen, Dorte

AU - Skougaard, Kristin

AU - Qvortrup, Camilla

AU - Vistisen, Kirsten

AU - Fromm, Anna-Lene Gunge

AU - Jørgensen, Trine Lembrecht

AU - Kroll Bjerregaard, Jon

AU - Hoegdall, Estrid

AU - Jensen, Benny V

PY - 2011

Y1 - 2011

N2 - The efficacy and safety of concurrent administration of irinotecan with the two monoclonal antibodies cetuximab and bevacizumab as fourth line therapy in heavily pretreated patients with metastatic colorectal cancer were evaluated.

AB - The efficacy and safety of concurrent administration of irinotecan with the two monoclonal antibodies cetuximab and bevacizumab as fourth line therapy in heavily pretreated patients with metastatic colorectal cancer were evaluated.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antibodies, Monoclonal

KW - Antibodies, Monoclonal, Humanized

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Camptothecin

KW - Colorectal Neoplasms

KW - Female

KW - Humans

KW - Liver Neoplasms

KW - Male

KW - Middle Aged

KW - Mutation

KW - Proto-Oncogene Proteins

KW - Retrospective Studies

KW - Survival Rate

KW - Treatment Outcome

KW - ras Proteins

UR - https://www.scopus.com/pages/publications/79955632360

U2 - 10.3109/0284186X.2010.546369

DO - 10.3109/0284186X.2010.546369

M3 - Journal article

C2 - 21529301

SN - 0284-186X

VL - 50

SP - 574

EP - 577

JO - Acta Oncologica

JF - Acta Oncologica

IS - 4

ER -

Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this